Analysts reboot SentinelOne stock price targets after earnings
This is what could happen next to SentinelOne shares.
Fed's Bostic: it is 'time to move' on rate cuts, but wants to be sure
Bostic said he will want to see confirmation from the monthly jobs report and two inflation reports due before the Fed's Sept. 17-18 meeting that the economic trends are continuing. "I don't want us to be in a situation where we cut, and then we have to raise rates again: that would be a very bad outcome" because it would undermine people's confidence in the Fed, he said at an event organized by the Stanford Club of Georgia and the Stanford Black Alumni Association–Atlanta. The Fed has kept its policy rate in the 5.25%-5.50% range for more than year to bring down high inflation.
Why Electric Vehicle (EV) Stocks Skidded Into Losses on Wednesday
Sentiment on the sector wasn't helped by the latest developments in Asia.
Prediction: This Under-the-Radar Tech Stock Will Outperform Nvidia and Apple by 2030
One tech stock is poised to outperform Apple and Nvidia over the next five years. Find out who it is and why the stock looks undervalued today.
Influencer Marketing’s Brewing Hangover
A judge’s ruling in a suit against influencers who marketed vodka but allegedly didn’t disclose the business relationship could encourage more consumer lawsuits.
Mexico stocks lower at close of trade; S&P/BMV IPC down 0.07%
Investing.com – Mexico stocks were lower after the close on Wednesday, as losses in the Materials, Consumer Staples and Telecoms Services sectors led shares lower.
Why Nike Stock Fell Again Today
Despite posting Q2 sales and earnings that beat Wall Street's expectations, Foot Locker delivered some bad news for Nike today.
Russia stocks lower at close of trade; MOEX Russia down 1.05%
Investing.com – Russia stocks were lower after the close on Wednesday, as losses in the Mining, Oil&Gas and Telecoms sectors led shares lower.
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Shares of Gilead Sciences, Bristol-Myers Squibb, and Vertex Pharmaceuticals got a boost from clinical trial results and regulatory decisions.